Moreover, by exploring skin rash with the more thorough tripartite skin grading score for the evaluation of acneiform skin eruptions induced by EGFR inhibition that has been developed by Wollenberg and Moosmann (WoMo score)6 (the main secondary endpoint in the EVITA trial), less severe skin toxicity (measured with part C of this score) was found in patients treated with Reconval K1 cream. This evidence concerns the gene EGFR and Skin rash.